Biosense Webster today launched its HelioStar balloon ablation catheter in Europe.
Johnson & Johnson’s subsidiary Biosense Webster launched the radiofrequency balloon ablation catheter for catheter-based cardiac electrophysiological mapping of the atria when used with a multi-channel RF generator.
According to the company, more than 11 million people in Europe have AFib. The expectation is that by 2030, the number of people with the heart condition will increase by up to 70%. Catheter ablation is typically recommended as the first treatment option for the condition and has been associated with improved quality of life and significant reductions in AFib burden, Biosense Webster said in a news release.